;
  • Report:  #1148951

Complaint Review: Harris Lydon - Nationwide

Reported By:
ConsumerFraud - Robert, Georgia,
Submitted:
Updated:

Harris Lydon
Nationwide, USA
Web:
N/A
Categories:
Tell us has your experience with this business or person been good? What's this?
Report Attachments

How my chosen biotech startup was dissolved and why

15 May 2014, 9:24 am

I “invested” $88,208 in this POS (piece of s***). It could have been worse. I tried to invest $100,000, but it was oversubscribed and I got cut back. Amazingly, there were other idiots. The date on my senior convertible promissory note was June 29, 2007. It took the company four and half years and many millions of dollars to go broke. But broke it went.

 

In my files I have a very impressive 44-page PowerPoint from the then president and CEO, Harold H. Shlevin. The first slide contained Tikvah Therapeutics’s “Highlights.”

 

Looking back, I now especially love the lines “Proven, experienced management team” and “A focused strategy emphasizing risk reduction.”

I spoke to Dr. Shlevin this morning. He said the company needed to raise more money during 2008, but funding for biotechs dried up completely during the financial crisis. The company drastically cut expenses. And in the process, the majority shareholder, namely Paramount, fired Dr. Shlevin, who actually didn’t know about the Dissolution Certificate, until I told him this morning.

The obvious lesson here is that startups are dicey, with biotech startups perhaps the diciest (but also among the most rewarding).

I’m writing this now because I had warrants in the company which were expiring today, May 15. And Muriel, my CFO, wondered what we should do with them? (Answer: frame them and hang them in the bathroom.)

The second lesson is that startups coddle and love you until they have your money. Then you’ll never hear from them again — ever. In all those years, Tikvah had never sent me a quarterly report, an annual report or even a copy of the Certificate of Dissolution. I spent several hours yesterday on the phone and the web checking into what happened to Tikvah. The web was useless. I finally got a copy of the Certificate from the salesman, Harris Lydon, who sold me the stock in Tikvah while he worked for Paramount Bio-Capital, the investment banker who created Tikvah, stuffed it with three drugs, found the management to run it and then promoted Tikvah to unsuspecting investors (like me). Paramount was and is still headed by a fellow called Dr. Lindsay Rosenwald. There’s a glowing biography on Lindsay on Wikipedia, which fails to mention his many failures, like Tikvah and some of the others of his I sadly invested in. Many apparently went down in 2008.

I mention Tikvah not because I want your sympathy, but as a lesson in what might happen to you if you invest in startups.

Yes, startups. Even with my Tikvah wipe-out, I still think it’s reasonable to have 10% of your portfolio in startups, with the following caveats:

+ When choosing which to invest in, the key element is the quality of the management, their brilliance and their hunger.

+ You’ll never see the quality of startup which professional VCs see. Hence, you’re already at a disadvantage.

+ Say NO to 99% of startups you see. OK, 98% if you want to be gutsy.

+ If you invest in ten startups, expect nine to go bust. You won’t be disappointed.

+ Make sure your startup has enough money to take it through the economy’s next boom-and-bust cycle. Most startups underestimate their marketing costs. Biotech companies are a money-suck beyond anything you ever imagined. It can take 10-15 years before the FDA approves your compound. Most likely, they won’t. The FDA is increasingly risk adverse — afraid of off-label abuse and disasters that might happen after years of use — e.g. Thalidomide and its affect on pregnant women.

+ Get a written agreement to be sent regular quarterly and annual reports. Get monthly reports if you can.

+ Become an advisor to the company. But check that management listens. Most don’t.

+ Don’t get involved with startups if you’re over 60. You don’t need the agita. And you won’t be around before yo get a dividend or get taken over, or go IPO.



1 Updates & Rebuttals

ConsumerFraud

Georgia,
DH Blair Indictment for Racketeering

#2Author of original report

Fri, May 23, 2014

13
1

Share
Comment

D.H. Blair & Co. Indicted for Racketeering

Share1
Ripoffreport Report Image

Two years after D.H. Blair & Co. ceased operations, a New York grand jury indicted the retail brokerage firm and several of its executives and employees on racketeering charges, prosecutors said Thursday.

The executives, including Kenton Wood, the firm's chairman, and Alan Stahler and Kalman Renov, its vice chairmen, face up to 25 years in state prison if they are convicted on the felony charges.

The indictment also names 12 other D.H. Blair employees including Vito Capotorto, the firm's head trader, and Alfred Palagonia, the top-producing broker.

 

 

 

The 173-count indictment charges that the firm defrauded its own customers, other investors, other brokerage firms and securities regulators from 1989 through 1998. The charges include manipulating the prices of IPOs and engaging in illegal sales tactics, including dodging customers' orders to sell stocks.

Prosecutors noted that more than 50,000 customers invested with the firm and that it made "large profits," but they said the extent of customers' losses was unknown.

All defendants surrendered and pleaded not guilty Thursday afternoon.

"D.H. Blair & Co. and its executives are innocent of these charges, absolutely deny that they engaged in any criminal activity whatsoever and anticipate their ultimate vindication," said Andrew M. Lawler, a lawyer for the firm and its executives. "The indictment is erroneously based on novel theories of securities law which we believe cannot be the basis for criminal charges."

Each defendant was also charged with securities fraud and scheme to defraud in the first degree. Both charges are felonies punishable by up to four years in state prison, but convictions on the racketeering charges would control the sentencing, prosecutors said.

J. Morton Davis, who joined Blair in 1961 and bought a majority stake seven years later, was not named in the indictments. Davis gave the retail brokerage arm of the company to his family in 1992, retaining control of the investment banking division, D.H. Blair Investment Banking, which continues to operate today. Stahler and Renov are his sons-in-law. Davis did not return calls for comment.

The indictments also accused some Blair employees of falsifying business records, suppressing complaints and giving false testimony. Brokers at D.H. Blair obtained boxes of computer printouts owned by the firm Salomon Smith Barney and containing the names of more than 10,000 of its customers, said Daniel J. Castelman, chief of the investigation division for the Manhattan District Attorney. Brokers from D.H. Blair cold-called many of the people named on the list, he said.

Castelman said Salomon Smith Barney is not involved in the investigation "except as the victim of a theft."

Duncan King, a spokesman for Salomon Smith Barney, declined to comment.

It was unclear whether investors could expect any restitution beyond $2.4 million obtained byNASD Regulation in 1998.

Castelman said in a telephone interview that restitution could be included in a plea agreement, or a judge could order it as part of a conviction.

"It is the policy of this office to try to return criminal proceeds to the victim," he said.

"It's clear to us that they have substantial assets," he said, referring to the defendants. "Some were making more than $1 million a year."

Prosecutors said they built a case from leads obtained in an investigation of A.R. Baron, a penny-stock brokerage firm that filed for bankruptcy protection in 1996. Andrew Bressman, a top-producing broker at D.H. Blair, left the firm in 1992 to found Baron with a group of former Blair brokers. In 1997, he pleaded guilty to one count of enterprise corruption and one count of grand larceny, agreeing to cooperate with the district attorney. He has not yet been sentenced.

In 1997, the New York Stock Exchange censured Blair and fined it $250,000, alleging the firm did not take proper steps to prevent misconduct by its brokers. Later, the National Association of Securities Dealers censured the firm and fined it $4.3 million for allegedly overcharging retail investors. Concurrent with that action, Wood and Capotorto paid a combined $525,000 in fines, neither admitting nor denying wrongdoing. In 1998, Blair set up a $2.25 million restitution fund after settling state investigators' charges of abusive sales practices.

 

 

Reports & Rebuttal
Respond to this report!
Also a victim?
Repair Your Reputation!
//